Davide Pastorelli - Publications

Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study).

Journal: Frontiers in oncology

Published: November 21, 2024

Nutritional Intervention for the Elderly during Chemotherapy: A Systematic Review.

Journal: Cancers

Published: July 17, 2024

ABO-Incompatible Orthotopic Liver Transplant as a Rescue Strategy for Fulminant Hepatic Failure in a Recipient With Breast Cancer: Highlights on Transplant Management.

Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

Published: October 27, 2023

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.

Journal: Targeted oncology

Published: May 16, 2022

Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 04, 2020

Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: January 13, 2019

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 05, 2018

Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.

Journal: Pharmacological research

Published: January 30, 2018

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Journal: The Lancet. Oncology

Published: November 14, 2017

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.

Journal: British journal of cancer

Published: October 25, 2017

Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib.

Journal: Hepatic oncology

Published: April 01, 2017

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 15, 2017